Cas:91241-12-2 N-[bis(dimethylamino)phosphorylimino-bis(dimethylamino)-λ5-phosphanyl]-N-methylmethanamine manufacturer & supplier

We serve Chemical Name:N-[bis(dimethylamino)phosphorylimino-bis(dimethylamino)-λ5-phosphanyl]-N-methylmethanamine CAS:91241-12-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

N-[bis(dimethylamino)phosphorylimino-bis(dimethylamino)-λ5-phosphanyl]-N-methylmethanamine

Chemical Name:N-[bis(dimethylamino)phosphorylimino-bis(dimethylamino)-λ5-phosphanyl]-N-methylmethanamine
CAS.NO:91241-12-2
Synonyms:I05-3356;MFCD00192491;PDPO;Tris-dimethylamino-phosphornitrido-phosphoryl-bis-dimethylamid
Molecular Formula:C10H30N6OP2
Molecular Weight:312.33200
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:354.9ºC at 760mmHg
Density:1.1g/cm3
Index of Refraction:n20/D 1.495(lit.)
PSA:65.25000
Exact Mass:312.19600
LogP:1.84870

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3267 8/PG 2
Packing Group:


Contact us for information like I05-3356 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Tris-dimethylamino-phosphornitrido-phosphoryl-bis-dimethylamid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00192491 Use and application,I05-3356 technical grade,usp/ep/jp grade.


Related News: Under the sub-licensing agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply it to the drug firm. N-[bis(dimethylamino)phosphorylimino-bis(dimethylamino)-λ5-phosphanyl]-N-methylmethanamine manufacturer In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers. N-[bis(dimethylamino)phosphorylimino-bis(dimethylamino)-λ5-phosphanyl]-N-methylmethanamine supplier In 2004, the National Development and Reform Commission, the former Ministry of Health, and the Ministry of Finance jointly formulated and promulgated the Administrative Measures for the Configuration and Use of Large Medical Equipment. This method uses X-ray electronic computer tomography (CT) devices and medical magnetic resonance imaging equipment, digital subtraction angiography X-ray machines of 800 mA or more as the management products of large-scale medical equipment, Purchase and use need to be reported to the provincial health administrative department for approval before approval. However, in recent years, with the comprehensive coverage of medical insurance, such basic medical facilities are being widely popularized, and the relevant implementation rules have directly linked the number of equipment to the number of doctors. Therefore, as the demand for imaging equipment continues to increase, it will have a greater boosting effect on the upstream contrast agent and its raw material market. N-[bis(dimethylamino)phosphorylimino-bis(dimethylamino)-λ5-phosphanyl]-N-methylmethanamine vendor In 2004, the National Development and Reform Commission, the former Ministry of Health, and the Ministry of Finance jointly formulated and promulgated the Administrative Measures for the Configuration and Use of Large Medical Equipment. This method uses X-ray electronic computer tomography (CT) devices and medical magnetic resonance imaging equipment, digital subtraction angiography X-ray machines of 800 mA or more as the management products of large-scale medical equipment, Purchase and use need to be reported to the provincial health administrative department for approval before approval. However, in recent years, with the comprehensive coverage of medical insurance, such basic medical facilities are being widely popularized, and the relevant implementation rules have directly linked the number of equipment to the number of doctors. Therefore, as the demand for imaging equipment continues to increase, it will have a greater boosting effect on the upstream contrast agent and its raw material market. N-[bis(dimethylamino)phosphorylimino-bis(dimethylamino)-λ5-phosphanyl]-N-methylmethanamine factory ��With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.��